Xuling

Xuling Biotech is a clinical-stage biotechnology company based in Hangzhou, China, dedicated to the development of innovative gene therapies for ophthalmic and metabolic diseases. The company leverages its proprietary adeno-associated virus (AAV) vector platform to engineer long-lasting treatments that aim to replace the current standard of care involving frequent intraocular injections. Its lead program, XL001, is an investigational gene therapy for wet age-related macular degeneration (wAMD) that delivers a transgene encoding an anti-VEGF protein directly to the retina. By enabling the eye to produce its own therapeutic proteins, Xuling's approach seeks to significantly reduce the treatment burden for patients with chronic retinal conditions. The company is supported by leading venture capital firms, including Qiming Venture Partners and Lilly Asia Ventures.